Our Beviq cancer lawyers are helping victims who may have cancer from using Belviq. These Belviq cancer lawsuits are just beginning. An MDL class action is in the works. Our attorneys believe the prospects of large settlements in these cases are very high.
It may turn out that Belviq causes many types of cancer. Our law firm is looking at all cancers but our firm is focused on cancers along the digestive tract:
- Colorectal cancer
- Lung cancer
- Pancreatic cancer
So how did we get here? In January of 2020, the US Food and Drug Administration (FDA) announced that it was taking a look into the safety of the weight loss drug lorcaserin, or Belviq. On February 13, 2020, the manufacturer of Belviq, Eisai Inc., withdrew Belviq from the market at the FDA's request. So they don't like to call it a Belviq recall because they took it off the market. But it looks like a duck and quacks like a duck, right? This was a recall.
Lorcaserin cancer lawyers are alleging in lawsuits around the country that Eisai knew for years that Belviq might cause cancer and withheld this information from doctors and patients.
Belviq is a weight-loss drug. Arena developed Belviq in partnership with Eisai Co. Ltd. Its active ingredient, lorcaserin, makes patients feel full by altering chemicals in the brain. It is used along with diet and exercise to promote weight-loss, particularly in patients with diabetes, high cholesterol, or high blood pressure.
On June 27, 2012, the FDA approved lorcaserin (Belviq) for chronic weight management. This was the first anti-obesity medication to win approval since Orlistat in 1999. Why? These drugs have a history of having dangerous side effects. If you want proof of this, look at the $20 billion it took to settle the lawsuits involving fen-phen and Redux.
How did Belviq get approved? Everyone was excited that lorcaserin did not activate the serotonin 5-HT2B receptors like fen-phen. The FDA still made Arena do six post-marketing studies and report back on the cardiovascular outcomes of Belviq. No one was properly focused on the possible cancer risk.
Yet the problem was staring them right in the face. The FDA was even going back and forth with Arena about the results of a rat study that appeared to link the drug to increased cancer risk. Arena's response? Belviq drug elevated the levels of a certain hormone that only rats have. Seriously?
Clinical trials showed that taking Belviq increased the occurrence of cancer in patients. Many types of cancer were found, but pancreatic, colorectal, and lung cancer were found more frequently.
Lorcaserin was not approved at first due to concerns from laboratory studies on rats which linked the drug to the development of malignant tumors. After further study and evidence, the FDA approved the drug, understanding that cancer was a risk but determining that the benefits of weight loss would be greater than any of the risks they had investigated.
When the drug was approved by the FDA in 2012, Arena Pharmaceuticals (the company that originally marketed the drug) was required to begin a clinical trial. Among other side effects, the trial was meant to detect any increased risk of cancer. There were also concerns about heart valve damage since that had been a problem with previous weight-loss drugs.
The trial included 12,000 people over five years. Years later, the FDA has found that more patients taking the drug were diagnosed with cancer than those taking a placebo. As a result, the FDA now believes that the risks of Belviq outweigh its benefits.
In the study, all participants were either overweight or obese. Additionally, they either had an established cardiovascular disease or were 50 years old or older with type 2 diabetes and an additional cardiovascular risk factor. They were assigned either lorcaserin or a placebo. Researchers followed up with participants about three years after they started the medication.
Pancreatic, colorectal, and lung cancer were found in the lorcaserin group more frequently than other types of cancer.
The study revealed an imbalance in the number of patients diagnosed with cancer between the lorcaserin and placebo groups. Of the 12,000 participants in the study, "462 (7.7 percent) patients treated with lorcaserin were diagnosed with 520 primary cancers compared to the placebo group, in which 423 (7.1 percent) patients were diagnosed with 470 cancers."
Additionally, it was found that the risk of cancer increased the longer someone took lorcaserin. This increase was enough for the FDA to decide that Belviq simply presents too much of a risk. In other words, the increased likelihood of developing cancer does not outweigh the benefit of weight loss for these patients.
These studies led to to the Belviq recall and are the underpinning of the Belviq cancer lawsuits.
The starting point is you should ask your doctor, not a Belviq recall lawyer, right? The FDA has recommended that patients talk to their doctors immediately about an alternative medication or weight-loss program. It is generally safe to stop taking this medication right away. Is it always best to talk to your doctor before making changes to the medicines you take? Yes.
Belviq is known to produce drug dependence, especially if taken in incorrect dosages. If you are worried about stopping the medication, talk to your doctor. Be sure to monitor your blood sugar or pressure if applicable.
The Belviq safety recall and announcement that the drug was a human carcinogen has prompted a stream of Belviq lawsuits. Individuals who used Belviq for an extended period and subsequently developed cancer are now suing Eisai for knowingly releasing an unsafe drug without adequately warning of the risks of cancer.
The pandemic last year had a chilling effect on the volume of Belviq lawsuits, but it is expected to pick up considerably this year as things open up. As of May 2021, there are 13 Belviq cancer lawsuits pending in 12 different federal district courts and a similar number in the state courts. This number could easily triple over the next 6 months.
In April 2021, a group of plaintiffs in the pending Belviq cases filed a motion asking the Judicial Panel on Multidistrict Litigation (JPML) to create a new Belviq MDL.
If a new class action MDL is created, all Belviq cases pending in federal courts across the country would be consolidated into it. The consolidated cases would be assigned to a single judge for more efficient handling. All future Belviq cases filed around the U.S. would get transferred into the MDL.
After a period of discovery and fact gathering, a handful of Belviq lawsuits would be selected for trial. The results of those trials would then be used to negotiate a settlement of the remaining cases.
Settlement Amounts of Belviq Lawsuits
It is hard to speculate on what the settlement value of these cases might be. But we do know that cancer claims in mass torts like this case may resolve for settlements that exceed $500,000. Do our Belviq lawyers think the settlement amounts in the Belviq cases will be that high?Getting a Lawyer for Belviq Cancer Lawsuits
If you or someone you know has been diagnosed with cancer after taking Belviq or Belviq XR, our lawyers are here to fight for you. You can speak with one of our lorcaserin cancer lawyers at (800) 553-8082, or fill out an online form for a free consultation.